A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 1, 1997, Pages 37-41

  Doolan, Lawrence A ^a   Jones, Elizabeth F ^a   Kalman, Jonathan ^a   Buxton, Brian F ^a   Tonkin, Andrew M ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

cardiac surgery; cerdiopulmonary bypass; milrinone; positive inotropic agents

Indexed keywords

INOTROPIC AGENT; MILRINONE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEANING;

EID: 0031042363     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90250-0     Document Type: Article

References (14)

1. Royster RL, Butterworth JFIV, Prough DS, et al: Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting. Anesth Analg 72:29-36, 1991
2. Feneck RO: Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. Am Heart J 1995-1999, 1991 (suppl 121)
3. Vincent JL, Leon J, Melot BC, et al: Addition of phosphodiesterase inhibitors to adrenergic agents in acutely ill patients. Int J Cardiol 28: S7-S11, 1990
4. Levy JH: Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options. J Cardiothorac Vase Anesth 7:46-51, 1993 (suppl 2)
5. Hardy JF, Belisle S: Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: The Montreal Heart Institute experience. J Cardiothorac Vase Anesth 7:33-39, 1993 (suppl 2)
6. Erhardt PW, Hagedorn AA, Sabio M: Cardiotonic agents 3. A topographical model of the cardiac cAMP phosphodiesterase receptor. Mol Pharmacol 33:1-13, 1988
7. Leier CV: Current status of non-digitalis positive inotropic drugs. Am J Cardiol 69:120G-129G, 1992
8. Anderson JL: Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: Results of a multicenter study in the United States. Am Heart J 1956-1964, 1991 (suppl 121)
9. Monrad ES, McKay RG, Bairn DS, et al: Improvement in the indices of diastolic performance in patients with congestive heart failure with milrinone. Circulation 70:1030-1037, 1984
10. Remme WJ: Inodilator therapy for heart failure. Circulation 87: IV-97-IV-107, 1993 (suppl 4)
11. Packer M, Carver JR, Rodeheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. Results of the prospective randomized milrinone survival evaluation. N Engl J Med 325:1468-1475, 1991
12. Butterworth JF, Royster RL, Prielipp RC, et al: Amrinone in cardiac surgical patients with left ventricular dysfunction. Chest 104:1660-1667, 1993
13. Boldt J, Kling D, Zickmann B, et al: Efficacy of the phosphodiesterase inhibitor enoximone in complicated cardiac surgery. Chest 98:53-58, 1990
14. Copp MV, Hill AJ, Feneck RO: Overview of the effects of intravenous milrinone in acute heart failure following heart surgery. Eur J Anaesthesiol 2:35-41, 1992 (suppl 5)